What is Pinealon?
Pinealon is a synthetic tripeptide, a chain of three amino acids (Glu-Asp-Arg), developed at the St. Petersburg Institute of Bioregulation and Gerontology and sold in Russia as a dietary supplement for brain function. Its evidence consists of rat and cell culture studies (cells grown in a dish) from the developing group, including protection of rat offspring from prenatal hyperhomocysteinemia (high levels of the amino acid homocysteine before birth); no randomized human trial has been indexed, so PeptideAgent grades it animal-only. It has never been reviewed by FDA, is not an approved drug anywhere, and is prohibited in sport under WADA section S0, the anti-doping ban on unapproved substances.
Pinealon is a synthetic tripeptide (Glu-Asp-Arg) from the Khavinson family of short peptide bioregulators. It is also known as EDR peptide, Glu-Asp-Arg, L-glutamyl-L-aspartyl-L-arginine, Khavinson peptide, Pinealon peptide.
How does it work?
The developers propose that short peptides such as Pinealon enter cells and the nucleus and bind DNA to modulate gene expression, including genes involved in neuronal differentiation, antioxidant defense, and the pathogenesis of Alzheimer's disease. In rat neurons it reduced reactive oxygen species accumulation and necrosis under oxidative stress. These proposals rest on in vitro, molecular modeling, and rodent work from a single research group and have not been independently confirmed or tested in humans.
| Cluster | Cognitive and neuroprotective |
|---|---|
| Routes | Oral capsule (sold as a supplement in Russia); Subcutaneous or intranasal use described by sellers (no studies); Injection (rat studies) |
| Conditions studied | Cognitive decline and nootropic use |
| Record | v3, reviewed, verified Sep 30, 2026 |
Pinealon benefits: what the evidence shows
Published evidence comes from the Khavinson group in St. Petersburg. In rats with methionine induced hyperhomocysteinemia during pregnancy, Pinealon improved spatial orientation and learning in the offspring and reduced reactive oxygen species and necrotic cells in isolated cerebellar neurons. A 2020 review describes proposed effects on gene expression relevant to Alzheimer's disease based on cell and computational work. A Russian language review reports use of short peptides in older people, but no randomized controlled trial has been indexed and no independent laboratory has replicated the findings.
| Evidence type | Indexed studies | Participants (human) |
|---|---|---|
| Human randomized trials | 0 | n/a |
| Human observational studies | 0 | n/a |
| Animal studies | 2 | n/a |
| All indexed studies | 2 | n/a |
Human evidence
No indexed randomized controlled trial identified. A 2013 Russian language review from the developing group describes neuroprotective use of peptide bioregulators including short peptides in people of various ages, but design details are not available in an indexed abstract and it is not a controlled trial. No pharmacokinetic or safety study in humans has been published.
Animal evidence
In pregnant rats loaded with dietary methionine to induce hyperhomocysteinemia, Pinealon administration improved the offspring's spatial orientation and learning ability and decreased reactive oxygen species accumulation and the number of necrotic cells among isolated cerebellar neurons. In vitro work from the same group reports antioxidant and neuroprotective effects in neuronal cultures.
Key studies
| Study | Design and population | Outcome | Grade |
|---|---|---|---|
| Pinealon protects the rat offspring from prenatal hyperhomocysteinemia2012 PMID 22567179 | Rat study of maternal Pinealon treatment during methionine induced hyperhomocysteinemia in pregnancyPregnant rats and their offspring | Offspring of treated dams showed improved spatial orientation and learning and fewer necrotic cerebellar neurons with less reactive oxygen species accumulation | Evidence: Animal-only evidence |
| EDR peptide: possible mechanism of gene expression and protein synthesis regulation involved in the pathogenesis of Alzheimer's disease2020 PMID 33396470 | Review with molecular modeling and cell culture dataCell cultures and computational models | Proposes that Glu-Asp-Arg binds DNA and modulates expression of genes relevant to Alzheimer pathology; no human data | Evidence: Animal-only evidence |
Conditions studied
| Condition | Grade | Note |
|---|---|---|
| Cognitive decline and nootropic use | Not graded | Semax, selank, dihexa, cerebrolysin, and related compounds are marketed for cognition. Cerebrolysin has small clinical trials in stroke and dementia, mostly outside the United States. Semax and selank have Russian clinical literature but no indexed US or EU randomized trials. Dihexa and P21 are animal-only. |
Is Pinealon legal in the United States?
FDA and compounding status
Pinealon is not an FDA approved drug and is not part of any approved drug. As of the last verification date it does not appear in any FDA 503A category or on the list of withdrawn nominations, and it is not on the 503A bulks list. It is therefore outside FDA's interim policy, and a 503A pharmacy has no federal basis to compound it from bulk. It is not eligible for 503B outsourcing. Imported and research use only products are not verified for identity or purity.
WADA status
WADA prohibited. Athletes subject to anti-doping testing should treat this as prohibited at all times unless the current prohibited list says otherwise.
Regulatory timeline
No regulatory events recorded.
Full tracker for Pinealon or the category-wide tracker.
Email me when Pinealon's status changes
Email only. Alerts have not started yet; we will ask you to confirm before the first one. Unsubscribe any time.
What published studies of Pinealon used
Ranges below are reported from published studies and labeling only. PeptideAgent does not recommend doses or protocols.
Not established in human literature. Rat studies used research doses with no established human equivalent. Russian supplement labeling for Pinealon capsules is not based on any published dose finding study.
Routes reported
| # | Route |
|---|---|
| 1 | Oral capsule (sold as a supplement in Russia) |
| 2 | Subcutaneous or intranasal use described by sellers (no studies) |
| 3 | Injection (rat studies) |
Pinealon side effects
Side effects
| # | Reported side effect |
|---|---|
| 1 | No human safety data of any kind |
| 2 | Rodent studies did not report toxicity, but no formal toxicology has been published |
| 3 | Injection site reactions are plausible for injected products (not studied) |
Interactions
| # | Interaction |
|---|---|
| 1 | No interaction data exist in any species |
Contraindications
| # | Contraindication |
|---|---|
| 1 | No human use is supported by evidence |
| 2 | Pregnancy and breastfeeding (no human data) |
| 3 | Competitive athletes subject to WADA testing (prohibited at all times under S0) |
How do people access Pinealon legally?
Typical cost: Not available through licensed US channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity.
Access options
Not available
Not legally available for human use in the United States: no FDA approved product and no federal basis to compound it from bulk.
Not available
Not an FDA approved drug and not compoundable under 503A or 503B.
Outside the US
Sold as a supplement in Russia; imported and research use only products are not verified for identity or purity.
Access paths are checked against public regulatory records. Products labeled research use only are never listed.
Compare Pinealon
What's actually offered, and what that means for you
Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. PeptideAgent has not found an FDA warning letter or review that names pinealon. [9] [10] [11]
Being offered does not change the legal status of pinealon. Pinealon is not FDA approved and not on the 503A bulks list, so a pharmacy has no federal basis to compound it. [4] [12]
Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, Category 2 safety listings, and import alerts that let it detain shipments, rather than stopping every pharmacy. State pharmacy boards oversee pharmacies day to day, and their rules differ. [4] [6] [9] [13] [14] [15]
What that means for you
- A pharmacy that compounds pinealon is taking a regulatory risk: it has no federal basis to do so, and FDA has sent warning letters to compounders for the same thing. [9] [13]
- No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [6]
- State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [16]
- Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [17] [18]
- Identity, purity, sterility, and dose accuracy can vary from batch to batch. [4]
- Insurance rarely covers it, so you usually pay cash.
- For tested athletes, pinealon is prohibited under the WADA Prohibited List, whatever the source. Some entries apply only in competition or only to male athletes, so check the section that covers it. [7]
If you're going ahead anyway
These steps lower some risks. They do not make the product safe, and they do not give a pharmacy a federal basis to compound pinealon, with or without a prescription. [12]
Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [19] [20] [21]
What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [11] [21] [22]
Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [6] [23] [24] [25] [26] [27]
Check for:
- A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [6]
- A real evaluation by a licensed prescriber, not just an online form.
- A certificate of analysis for the specific batch.
Questions to ask
- Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [19]
- Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [11]
- Pharmacy: Is this made for me on a prescription written in my name? [22]
- Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [11] [21]
- Prescriber: What is the legal basis for a pharmacy to compound pinealon? Is it FDA approved or on the 503A bulks list? [6] [12]
- Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [11]
In Mississippi, there is no legitimate prescriber route for a peptide that is not FDA approved: licensed providers may not prescribe or supply one, and a patient who gets one on their own carries the risk alone. [16]
Frequently asked questions
What is pinealon?
Pinealon is a synthetic three amino acid peptide (Glu-Asp-Arg) from the St. Petersburg Institute of Bioregulation and Gerontology, sold in Russia as a dietary supplement for brain function. Its evidence is rat and cell culture work (cells grown in a dish) from the developing group, and it is not an approved drug anywhere. [1] [2]
Is Pinealon legal in the United States?
Pinealon is not an approved drug anywhere and has never been reviewed by FDA for compounding, so there is no FDA approved or lawfully compounded source of it for human use in the United States. It is sold as a supplement in Russia and imported or sold online as a research chemical. Possession is not a criminal matter, but no US clinic or pharmacy can lawfully dispense it. [4] [6]
Does Pinealon work for memory or brain aging?
There is no controlled human evidence. The published studies are from the developing laboratory in rats and cell cultures, where it improved learning in rat offspring exposed to prenatal hyperhomocysteinemia and protected neurons from oxidative stress. A Russian language review describes use in older people but is not a randomized trial. PeptideAgent grades the evidence animal-only. [1] [3]
What are the side effects of Pinealon?
No human safety data have been published. Rodent studies did not report toxicity, but formal toxicology is not available. Injected products carry the usual risks of unverified research chemicals, including contamination and incorrect identity. [1] [4]
How is Pinealon taken?
In Russia it is sold as oral capsules. Sellers elsewhere describe subcutaneous and intranasal use. None of these routes or doses has been studied in humans; the only published dosing is in rats. [1]
How much does Pinealon cost?
It is not available through licensed US channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity. [4] [8]
Is Pinealon banned by WADA?
Yes. Pinealon has no approval from any government health authority as a medicine for human use, which places it in section S0 (non-approved substances) of the WADA Prohibited List. It is prohibited at all times. [7]
Pinealon vs Epitalon: what is the difference?
Both are short Khavinson peptides from the same St. Petersburg group. Epitalon is a tetrapeptide (Ala-Glu-Asp-Gly) marketed for longevity and telomere effects; Pinealon is a tripeptide (Glu-Asp-Arg) marketed for brain function. Epitalon was placed on the FDA Category 2 compounding list and its nomination was listed as withdrawn in April 2026; news reports said the advisory committee voted in July 2026 to recommend it for the 503A bulks list, but FDA's own briefing recommended against listing and FDA has not posted the vote. Pinealon has never been nominated. Neither has a randomized human trial indexed in English; the randomized trial often cited for epitalon tested the pineal extract Epithalamin, not the synthetic peptide. [2] [4] [5]
Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.
Sources
Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.
- [1]Arutjunyan A et al. Pinealon protects the rat offspring from prenatal hyperhomocysteinemia. Int J Clin Exp Med 2012PubMed 22567179, 2012
- [2]Khavinson V et al. EDR peptide: possible mechanism of gene expression and protein synthesis regulation involved in the pathogenesis of Alzheimer's disease. Molecules 2020PubMed 33396470, 2020
- [3]Umnov RS, Lin'kova NS, Khavinson VKh. Neuroprotective effects of peptide bioregulators in people of various age. Adv Gerontol 2013 (Russian language review)PubMed 24738258, 2013
- [4]FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 list and withdrawn nominations, current as of April 22, 2026)FDA, 2026
- [5]FDA Pharmacy Compounding Advisory Committee (July 2026 meeting on peptide nominations)FDA, 2026
- [6]FDA: Compounding and the FDA, questions and answersFDA, 2026
- [7]WADA Prohibited List, section S0 non-approved substancesWADA, 2026
- [8]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026
- [9]FDA: Compounding inspections, recalls, and other actions (warning letters to compounders)FDA
- [10]FDA warning letter 594743, April 1, 2020, to a state-licensed 503A compounding pharmacy (FDA warning letters database)FDA, 2020
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, September 30). Pinealon: evidence, legality, and access. https://peptideagent.ai/peptides/pinealon- HTML link
<a href="https://peptideagent.ai/peptides/pinealon">Pinealon: evidence, legality, and access</a>, PeptideAgent, updated September 30, 2026.